CL2007003046A1 - Compuestos derivados de fluoreno; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades neurodegenerativas como parkinson, isquemia cerebral, huntington, cancer, degeneracion muscular, psoriasis, trombosi - Google Patents

Compuestos derivados de fluoreno; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades neurodegenerativas como parkinson, isquemia cerebral, huntington, cancer, degeneracion muscular, psoriasis, trombosi

Info

Publication number
CL2007003046A1
CL2007003046A1 CL200703046A CL2007003046A CL2007003046A1 CL 2007003046 A1 CL2007003046 A1 CL 2007003046A1 CL 200703046 A CL200703046 A CL 200703046A CL 2007003046 A CL2007003046 A CL 2007003046A CL 2007003046 A1 CL2007003046 A1 CL 2007003046A1
Authority
CL
Chile
Prior art keywords
trombosi
huntington
parkinson
psoriasis
cancer
Prior art date
Application number
CL200703046A
Other languages
English (en)
Spanish (es)
Inventor
Fabienne Mailliet Pat Thompson
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38069221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2007003046A1 publication Critical patent/CL2007003046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200703046A 2006-10-24 2007-10-23 Compuestos derivados de fluoreno; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades neurodegenerativas como parkinson, isquemia cerebral, huntington, cancer, degeneracion muscular, psoriasis, trombosi CL2007003046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609331A FR2907453B1 (fr) 2006-10-24 2006-10-24 Nouveaux derives du fluorene,compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
CL2007003046A1 true CL2007003046A1 (es) 2008-05-30

Family

ID=38069221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703046A CL2007003046A1 (es) 2006-10-24 2007-10-23 Compuestos derivados de fluoreno; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades neurodegenerativas como parkinson, isquemia cerebral, huntington, cancer, degeneracion muscular, psoriasis, trombosi

Country Status (23)

Country Link
US (1) US8163750B2 (enExample)
EP (1) EP2078009B1 (enExample)
JP (1) JP5431944B2 (enExample)
KR (1) KR20090080948A (enExample)
CN (1) CN101528735A (enExample)
AR (1) AR063507A1 (enExample)
AU (1) AU2007310767A1 (enExample)
BR (1) BRPI0718202A2 (enExample)
CA (1) CA2664115A1 (enExample)
CL (1) CL2007003046A1 (enExample)
CO (1) CO6160311A2 (enExample)
CR (1) CR10690A (enExample)
EA (1) EA200970400A1 (enExample)
FR (1) FR2907453B1 (enExample)
IL (1) IL197887A0 (enExample)
MA (1) MA30904B1 (enExample)
MX (1) MX2009004049A (enExample)
NO (1) NO20091972L (enExample)
PE (1) PE20081261A1 (enExample)
TN (1) TN2009000086A1 (enExample)
TW (1) TW200825083A (enExample)
UY (1) UY30667A1 (enExample)
WO (1) WO2008049994A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
MX336687B (es) * 2009-06-30 2016-01-28 Siga Technologies Inc Tratamiento y prevencion de infecciones del virus del dengue.
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
DE102009054302A1 (de) * 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
CN113521394A (zh) * 2020-04-13 2021-10-22 浙江华臻医疗器械有限公司 一种脱细胞血管基质及其制备方法
CN119409635A (zh) * 2024-11-04 2025-02-11 河南师范大学 具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2476087A1 (fr) 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
US7258238B2 (en) 2002-07-11 2007-08-21 Gea Energy System (India) Limited Debris filter with a rotating debris extractor
GB0227948D0 (en) 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US20040163196A1 (en) 2003-02-21 2004-08-26 Mckenzie Rebecca Anne Dusting-cleaning sleeve
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
US7241754B2 (en) 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
KR101129215B1 (ko) 2003-06-27 2012-04-13 교와 핫꼬 기린 가부시키가이샤 Ｈｓｐ90 패밀리 단백질 저해제
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
AU2004200774A1 (en) 2003-07-07 2005-01-27 Holyrood Exports Pty Ltd Padlock Protector
JPWO2005006322A1 (ja) 2003-07-11 2006-08-24 コニカミノルタオプト株式会社 光ピックアップ装置、光ピックアップ装置に用いられる光学素子、及び光学素子の製造方法
EP1675861B1 (en) 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
EA010160B1 (ru) * 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
DE10354133A1 (de) 2003-11-19 2005-06-23 Phoenix Ag Fördergurt
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
WO2005072766A2 (en) 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
JP2005225787A (ja) 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
AR050084A1 (es) 2004-07-27 2006-09-27 Novartis Ag Derivados de bencimidazolona como inhibidores de hsp90
CN101027053A (zh) 2004-07-27 2007-08-29 诺瓦提斯公司 Hsp90抑制剂
KR101045324B1 (ko) 2004-08-11 2011-06-30 한국생명공학연구원 젤다나마이신 유도체 및 그 생합성 방법
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
CA2585939C (en) 2004-11-03 2013-06-04 K2 Concepts, Inc. Anti-microbial compositions and methods of making and using the same
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
GB0501535D0 (en) 2005-01-25 2005-03-02 Vernalis R&D Ltd Pyrimidothiophene compounds
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
FR2882361A1 (fr) 2005-02-22 2006-08-25 Aventis Pharma Sa Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation
TWI382015B (zh) 2005-02-25 2013-01-11 Serenex Inc 苯、吡啶及噠嗪衍生物
WO2006090094A1 (en) 2005-02-28 2006-08-31 Vernalis R & D Ltd Pyrimidothiophene compounds for use as hsp90 inhibitors
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
CA2598899A1 (en) 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Novel hsp90 inhibitor
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
KR20080004550A (ko) 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
GB2423328B (en) 2005-04-09 2007-02-28 Louver Lite Ltd Window blind system
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation

Also Published As

Publication number Publication date
JP2010507634A (ja) 2010-03-11
MX2009004049A (es) 2009-04-28
WO2008049994A1 (fr) 2008-05-02
FR2907453B1 (fr) 2008-12-26
FR2907453A1 (fr) 2008-04-25
UY30667A1 (es) 2008-05-31
NO20091972L (no) 2009-05-20
EA200970400A1 (ru) 2009-10-30
US8163750B2 (en) 2012-04-24
EP2078009B1 (fr) 2015-03-18
KR20090080948A (ko) 2009-07-27
MA30904B1 (fr) 2009-11-02
AU2007310767A1 (en) 2008-05-02
BRPI0718202A2 (pt) 2013-11-12
US20100130503A1 (en) 2010-05-27
CA2664115A1 (fr) 2008-05-02
JP5431944B2 (ja) 2014-03-05
TN2009000086A1 (en) 2010-08-19
EP2078009A1 (fr) 2009-07-15
CO6160311A2 (es) 2010-05-20
IL197887A0 (en) 2009-12-24
CN101528735A (zh) 2009-09-09
PE20081261A1 (es) 2008-10-15
CR10690A (es) 2009-07-23
AR063507A1 (es) 2009-01-28
TW200825083A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2008000046A1 (es) Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003046A1 (es) Compuestos derivados de fluoreno; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades neurodegenerativas como parkinson, isquemia cerebral, huntington, cancer, degeneracion muscular, psoriasis, trombosi
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0915084A2 (pt) composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0814542A2 (pt) Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2014002100A1 (es) Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa